SPY316.44-0.61 -0.19%
DIA261.12-1.88 -0.71%
IXIC10,461.13+27.48 0.26%

Ardelyx Submits New Drug Application To FDA For Tenapanor For Control Of Serum Phosphorus In Adult Patients With CKD On Dialysis

FREMONT, Calif., June 30, 2020 /PRNewswire/ --Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and

Benzinga · -

FREMONT, Calif., June 30, 2020 /PRNewswire/ --Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the submission of a New Drug Application (NDA) for tenapanor to the U.S. Food and Drug Administration (FDA) for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.